Redas Trepiakas

438 total citations
11 papers, 349 citations indexed

About

Redas Trepiakas is a scholar working on Pulmonary and Respiratory Medicine, Immunology and Oncology. According to data from OpenAlex, Redas Trepiakas has authored 11 papers receiving a total of 349 indexed citations (citations by other indexed papers that have themselves been cited), including 5 papers in Pulmonary and Respiratory Medicine, 5 papers in Immunology and 4 papers in Oncology. Recurrent topics in Redas Trepiakas's work include Immunotherapy and Immune Responses (5 papers), Prostate Cancer Treatment and Research (4 papers) and Bladder and Urothelial Cancer Treatments (3 papers). Redas Trepiakas is often cited by papers focused on Immunotherapy and Immune Responses (5 papers), Prostate Cancer Treatment and Research (4 papers) and Bladder and Urothelial Cancer Treatments (3 papers). Redas Trepiakas collaborates with scholars based in Denmark, United Kingdom and United States. Redas Trepiakas's co-authors include Anders Elm Pedersen, Inge Marie Svane, Annika Berntsen, Poul Geertsen, Per thor Straten, Torben Lorentzen, Julia S. Johansen, Mads Hald Andersen, Özcan Met and Lynn Wenandy and has published in prestigious journals such as Journal of Clinical Oncology, European Urology and Vaccine.

In The Last Decade

Redas Trepiakas

11 papers receiving 345 citations

Peers

Countries citing papers authored by Redas Trepiakas

Since Specialization

Citations

This map shows the geographic impact of Redas Trepiakas's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Redas Trepiakas with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Redas Trepiakas more than expected).

Fields of papers citing papers by Redas Trepiakas

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Redas Trepiakas. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Redas Trepiakas. The network helps show where Redas Trepiakas may publish in the future.

Co-authorship network of co-authors of Redas Trepiakas

This figure shows the co-authorship network connecting the top 25 collaborators of Redas Trepiakas. A scholar is included among the top collaborators of Redas Trepiakas based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Redas Trepiakas. Redas Trepiakas is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

11 of 11 papers shown

#	Work	Indexed citations
1	CYCLONE 2: A phase 2/3, randomized, placebo-controlled study of abiraterone acetate plus prednisone with or without abemaciclib in patients with metastatic castration-resistant prostate cancer. 2022 ·Journal of Clinical Oncology ·Matthew R. Smith, Neeraj Agarwal, Tilman Todenhöfer, Josep M. Piulats, Jae‐Lyun Lee, Redas Trepiakas, Arpit Rao, Lisa G. Horvath, Andrew Lithio, (unknown), (unknown), (unknown), Christopher J. Sweeney	3
2	Real-world Treatment Patterns and Overall Survival in Locally Advanced and Metastatic Urothelial Tract Cancer Patients Treated with Chemotherapy in Denmark in the Preimmunotherapy Era: A Nationwide, Population-based Study 2020 ·European Urology Open Science ·(unknown), (unknown), Henriette Lindberg, Andreas Carus, Anne Birgitte Als, Niels Viggo Jensen, Gry Assam Taarnhøj, Redas Trepiakas, Charlotte Suetta, Lars Haukali Omland, Helle Pappot	20
3	Impact of Abiraterone Acetate plus Prednisone or Enzalutamide on Patient-reported Outcomes in Patients with Metastatic Castration-resistant Prostate Cancer: Final 12-mo Analysis from the Observational AQUARiUS Study 2019 ·European Urology ·Antoine Thiery-Vuillemin, Mads Hvid Poulsen, É. Lagneau, Guillaume Ploussard, Alison Birtle, (unknown), (unknown), Elias Pintus, Redas Trepiakas, Florence Lefresne, Martin Lukáč, Suzy Van Sanden, (unknown), Alison Reid	43
4	Impact of abiraterone acetate plus prednisone or enzalutamide on fatigue and cognition in patients with metastatic castration-resistant prostate cancer: initial results from the observational AQUARiUS study 2018 ·ESMO Open ·Antoine Thiery-Vuillemin, Mads Hvid Poulsen, É. Lagneau, Guillaume Ploussard, Alison Birtle, (unknown), (unknown), Elias Pintus, Redas Trepiakas, Laurent Antoni, Martin Lukáč, Suzy Van Sanden, (unknown), Alison Reid	32
5	Six-month patient-reported outcome (PRO) results from AQUARiUS, a prospective, observational, multicenter phase 4 study in patients (Pts) with metastatic castration-resistant prostate cancer (mCRPC) receiving abiraterone acetate + prednisone (AAP) or enzalutamide (ENZ). 2018 ·Journal of Clinical Oncology ·(unknown), Mads Hvid Poulsen, Louis-Marie Dourthe, Redas Trepiakas, É. Lagneau, Elias Pintus, (unknown), Alison Birtle, Guillaume Ploussard, Hervé Besson, Martin Lukáč, Paul Robinson, (unknown)	3
6	Variability in prostate and seminal vesicle delineations defined on magnetic resonance images, a multi-observer, -center and -sequence study 2013 ·Radiation Oncology ·Tufve Nyholm, Joakim Jönsson, Karin Söderström, Per Bergström, (unknown), Gunilla Frykholm, C.F. Behrens, Poul Geertsen, Redas Trepiakas, (unknown), Azmat Sadozye, Jawaher Ansari, H. McCallum, J. Frew, R. McMenemin, Björn Zackrisson	37
7	Vaccination with autologous dendritic cells pulsed with multiple tumor antigens for treatment of patients with malignant melanoma: results from a phase I/II trial 2010 ·Cytotherapy ·Redas Trepiakas, Annika Berntsen, Sine Reker Hadrup, (unknown), Poul Geertsen, Per thor Straten, Mads Hald Andersen, Anders Elm Pedersen, (unknown), Torben Lorentzen, Julia S. Johansen, Inge Marie Svane	66
8	Addition of interferon-alpha to a standard maturation cocktail induces CD38 up-regulation and increases dendritic cell function 2009 ·Vaccine ·Redas Trepiakas, Anders Elm Pedersen, Özcan Met, Inge Marie Svane	29
9	Comparison of α-Type-1 polarizing and standard dendritic cell cytokine cocktail for maturation of therapeutic monocyte-derived dendritic cell preparations from cancer patients 2008 ·Vaccine ·Redas Trepiakas, Anders Elm Pedersen, Özcan Met, (unknown), Annika Berntsen, Inge Marie Svane	32
10	Therapeutic Dendritic Cell Vaccination of Patients With Metastatic Renal Cell Carcinoma 2008 ·Journal of Immunotherapy ·Annika Berntsen, Redas Trepiakas, Lynn Wenandy, Poul Geertsen, Per thor Straten, Mads Hald Andersen, Anders Elm Pedersen, Mogens H. Claësson, Torben Lorentzen, Julia S. Johansen, Inge Marie Svane	82
11	Dendritic cell based vaccination in combination with IL-2 as a treatment for advanced renal cell carcinoma patients: Results from a phase I/II trial 2006 ·Journal of Clinical Oncology ·Annika Berntsen, Poul Geertsen, Redas Trepiakas, Lynn Wenandy, Mads Hald Andersen, Per thor Straten, Travis D. Lorentzen, (unknown), Hans Erik Johnsen, Inge Marie Svane	2

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact